availability, price and affordability of cardiovascular medicines 2001-2006
DESCRIPTION
Availability, price and affordability of cardiovascular medicines 2001-2006. Richard Laing for Alexandra Cameron & Maaike van Mourik International Conference on Improving the Use of Medicines (ICIUM) November 2011. Presentation outline. Introduction & Background Methodology Results - PowerPoint PPT PresentationTRANSCRIPT
1
Availability, price and affordability of cardiovascular medicines
2001-2006
Richard Laing for Alexandra Cameron & Maaike van Mourik
International Conference on Improving the Use of Medicines
(ICIUM)November 2011
2
Presentation outline
• Introduction & Background• Methodology• Results
– Availability– Pricing– Affordability
• Conclusions & policy options• Future research agenda
3
Introduction & Background• Cardiovascular diseases: 30% of deaths worldwide,
80% of which in developing countries
• WHO-PREMISE study– Many patients did not get medicines needed for adequate
management.• Non-WHO studies
– Problems with availability, pricing and affordability• WHO report on chronic disease medicines
(30 surveys)– Poor availability and affordability
• Aim: Secondary analysis of price, availability and affordability of CVD medicines in 36 developing countries that have undertaken WHO/HAI surveys
4
Methodology• WHO/HAI data
– Standardized data collection– Prices as Median Price Ratios (MPRs)– Medicines: Atenolol 50mg, Captopril 25mg,
Hydrochlorothiazide (HCT) 25mg, Losartan 50mg and Nifedipine retard 20mg.
• Secondary analysis– Adjustments for inflation and purchasing power– Analysis by World Bank Income Groups and WHO
regions.
5
Country listLow incomeChadEthiopia (2004)Ghana (2004)India-Chennai (2004)India-Haryana (2004)India-Karnataka (2004)India-Maharashtra 12 districts (2004)India-Maharashtra 4 regions (2005)India-Rajasthan (2003)India-West BengalKenya (2004)Kyrgyzstan (2005)Mali (2004)Mongolia (2004)Nigeria (2004)Pakistan (2004)Sudan-Gadarif (2006)Sudan-Khartoum (2005)Sudan-Kordofan (2006)Tajikistan (2005)Tanzania (2004)Uganda (2004)
Uzbekistan (2004)Yemen (2006)
Lower-middle incomeArmenia (2001)Cameroon (2002)China-Shandong Province (2004)China-Shanghai (2006)El-Salvador (2006)Fiji (2004)Indonesia (2004)Jordan (2004)Morocco (2004)Peru (2005) Philippines (2005)Sri Lanka (2001)Syria (2003)Tunisia (2004)
Upper-middle incomeBrazil-Rio de Janeiro (2001)Kazakhstan (2004)Lebanon (2004)Malaysia (2004)South Africa - Kwazulu Natal (2001)
High IncomeKuwait (2004)United Arab Emirates (2006)
p.21 of the report
6
Results: Availability (%)
0
10
20
30
40
50
60
70
80
Atenolol Captopril Hydrochloro-thiazide
Losartan Nifedipine All
Perc
enta
ge a
vaila
bilit
y
Public sector LPG Public sector OB Private sector LPG Private sector OB
7
Results: Availability by WBIGPublic sector percentage availability (weighted)
Atenolol Captopril Hydrochloro-thiazide Losartan Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB LPG OB LI 40.7 0.8 18.6 1.4 15.0 0.4 2.2 0.0 24.5 0.2 20.8 0.6 LMI 17.8 3.8 59.4 8.7 51.3 0.0 8.6 12.1 20.4 21.5 32.6 9.0 UMI 5.0 3.3 5.0 66.7 33.3 0.0 0.0 30.0 35.0 0.0 14.4 21.4 HI 93.0 10.5 81.3 5.6 46.9 0.0 0.0 72.2 50.0 100.0 60.3 38.1
All 38.9 2.3 31.5 9.1 27.7 0.5 3.7 10.4 26.0 11.7 26.3 6.8
Private sector percentage availability (weighted)
Atenolol Captopril Hydrochloro-thiazide Losartan Nifedipine All
LPG OB LPG OB LPG OB LPG OB LPG OB LPG OB LI 79.7 32.5 25.9 24.0 35.5 1.7 46.0 5.7 74.8 13.0 52.3 17.0 LMI 59.1 38.9 83.5 39.4 64.3 8.9 37.8 42.9 45.6 38.6 58.8 33.9 UMI 72.3 66.8 68.5 84.4 55.5 21.7 15.0 66.7 82.1 36.9 60.1 57.7 HI 76 98.0 16.7 94.0 50.0 0.0 0.0 100.0 34.8 98.0 39.4 85.0 All 73.3 42.8 59.4 36.5 45.9 6.7 38.6 29.8 65.6 26.5 57.3 29.2
8
Results: Procurement pricing• Public sector procurement
• Procurement vs. public sector patient pricing– Mark-up – Taxes– Procurement at a different price– Cross-subsidizing
02468
10121416
Atenolol Captopril HCT Nifedipine All
CPI a
djus
ted
MPR
Generic Brand
MPR = 1
9
Results: Patient pricing
0
20
40
60
80
100
120
140
160
Atenolol Captopril Hydrochloro-thiazide
Nifedipine All
CPI a
nd P
PP a
djus
ted
MPR
Public sector LPG Public sector OB Private sector LPG Private sector OB
Price ratio's in the public & private sector
10
Results: Patient pricing by WBIG
Patient MPRs (MSH2003, CPI and PPP adjusted) for the LPG (weighted averages) in the public and private sector. Atenolol Captopril Hydrochloro-
thiazide Nifedipine All
Public Private Public Private Public Private Public Private Public Private LI 15.7 21.0 7.2 12.4 40.5 85.2 9.8 11.8 15.9 35.6 LMI 40.2 41.5 6.9 14.7 12.0 66.6 9.5 27.8 15.3 45.7 UMI 13.2 8.9 15.2 36.0 9.5 11.1 12.4 22.4 HI 26.8 10.7 55.2 13.9 38.5 All 23.0 25.8 7.0 12.7 25.0 73.0 9.7 15.0 15.5 30.2
11
Results: Private sector brand premiums
0.0
1.0
2.0
3.0
4.0
5.0
6.0
Atenolol Captopril Nifedipine All
Rel
ativ
e br
and
prem
ium
LI LMI UMI HI All
12
Results: Affordability• Number of day's wages the lowest-paid
government worker needed to purchase one month of chronic treatment– Large variations, on average 1.8 day's wages for
single medicine– Most affordable: atenolol 50mg (1.1 day's wages)– High income areas more affordable than low income
• Note:– Average income often below lowest government wage– Need for multiple medicines
13
Conclusions & policy options• Availability
– Focus on small group of medicines from national STG– Increase public sector funding for NCD medicines– Private sector distribution of publicly subsidized
medicines• Procurement
– Some countries: can improve on procurement prices• Patient prices
– Lower taxes & tariffs– Promote the use of generics– Reduce mark-ups